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A b s t r a c t
Introduction: In large-animal acute myocardial infarction (AMI) models, Wharton’s jelly (umbilical cord matrix) mesenchymal 
stem cells (WJMSCs) effectively promote angiogenesis and drive functional myocardial regeneration. Human data are lacking.
Aim: To evaluate the feasibility and safety of a novel myocardial regeneration strategy using human WJMSCs as a unique, allo-
genic but immuno-privileged, off-the-shelf cellular therapeutic agent.
Material and methods: The inclusion criterion was first, large (LVEF ≤ 45%, CK-MB > 100 U/l) AMI with successful infarct-re-
lated artery primary percutaneous coronary intervention reperfusion (TIMI ≥ 2). Ten consecutive patients (age 32–65 years, peak 
hs-troponin T 17.3 ±9.1 ng/ml and peak CK-MB 533 ±89 U/l, sustained echo LVEF reduction to 37.6 ±2.6%, cMRI LVEF 40.3 ±2.7% 
and infarct size 20.1 ±2.8%) were enrolled.
Results: 30 × 106 WJMSCs were administered (LAD/Cx/RCA in 6/3/1) per protocol at ≈ 5–7 days using a cell delivery-dedicated, 
coronary-non-occlusive method. No clinical symptoms or ECG signs of myocardial ischemia occurred. There was no epicardial flow 
or myocardial perfusion impairment (TIMI-3 in all; cTFC 45 ±8 vs. 44 ±9, p = 0.51), and no patient showed hs-troponin T elevation 
(0.92 ±0.29 ≤ 24 h before vs. 0.89 ±0.28 ≤ 24 h after; decrease, p = 0.04). One subject experienced, 2 days after cell transfer, 
a transient temperature rise (38.9°C); this was reactive to paracetamol with no sequel. No other adverse events and no significant 
arrhythmias (ECG Holter) occurred. Up to 12 months there was one new, non-index territory lethal AMI but no adverse events that 
might be attributable to WJMSC treatment.
Conclusions: This study demonstrated the feasibility and procedural safety of WJMSC use as off-the-shelf cellular therapy in 
human AMI and suggested further clinical safety of WJMSC cardiac transfer, providing a basis for randomized placebo-controlled 
endpoint-powered evaluation.
Key words: myocardial regeneration, Wharton’s jelly mesenchymal stem cells, human umbilical cord matrix, acute myocardial 
infarction, first-in-man, safety, feasibility.
Introduction
Current cellular treatment strategies aimed to stim-
ulate cardiac regeneration in human acute myocardial 
infarction (AMI) suffer from lack of highly potent ther-
apeutic cells available ad hoc in sufficient numbers [1].
Wharton’s jelly mesenchymal stem cells (WJMSCs) 
are a  small population of multipotent progenitor cells 
naturally present in the human umbilical cord matrix [2]. 
In the ongoing search for the best stem cell to stimu-
late myocardial regeneration in AMI [3], WJMSCs are an 
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attractive candidate [4] for a  readily available “off-the-
shelf” cellular regenerative product for human use for 
several reasons. First, the umbilical cord is one of the 
most easily reached stem cell sources in the absence of 
ethical concerns associated with using embryo-derived 
stem cells [5, 6]. Secondly, WJMSCs spontaneously se-
crete numerous pro-angiogenic factors, such as vascular 
endothelial growth factor (VEGF), angiopoietin-1, HGF 
and transforming growth factor β1 (TGF-β1) [7], and the 
release of pro-angiogenic molecules is accompanied by 
evidence of functional angiogenic potency in the infarct-
ed mammalian heart [7–10]. Furthermore, WJMSCs show 
spontaneous expression of a  number of early cardiac 
transcription factors in addition to their natural expres-
sion of core markers of undifferentiated human embry-
onic stem cells [11]. Wharton’s jelly mesenchymal stem 
cells are more efficient in terms of stem cell potency 
than, for instance, bone marrow-derived stem cells pre-
dominantly used to date [5]. 
Wharton’s jelly mesenchymal stem cells are nat-
urally chemoattracted to the cardiac tissue, and they 
possess functional ability to populate the ventricular 
myocardium [12]. Indeed, in animal models, WJMSCs 
effectively induce angiogenesis [8–10] and show spon-
taneous differentiation into cardiac myocytes and en-
dothelial cells [8, 9, 13], a process consistent with the 
early findings in cardiomyocyte-conditioned medium 
WJMSC cultures [2]. In addition, recent evidence shows 
that WJMSCs can be successfully expanded ex vivo with 
high genomic stability, full clonogenic potential and 
full multilineage differentiation capacity, and with fully 
functional angiogenic potency, yielding large quantities 
of therapeutic cells available “when needed” and in 
“as-needed” numbers [7]. 
Wharton’s jelly mesenchymal stem cells use is free of 
the logistic problems of autologous cell harvest in clini-
cally unstable patients and circumvents the problem of 
the generally low (and variable) autologous regenerative 
cell yields [14, 15]. This may be particularly relevant in 
AMI, when the biologic window for therapeutic cell deliv-
ery does not allow any long-term culture and/or cell ma-
nipulation or lineage-specific expansion of autologous 
cells [16]. Although WJMSCs are a natural candidate for 
application in the setting of AMI in man, human feasi-
bility and safety data are lacking [17, 18] (NB. PubMed 
exploration using various combinations of the terms 
“Wharton’s jelly, umbilical cord matrix, infarction, heart, 
cardiac, myocardial, clinical, experimental, man or hu-
man”; last search performed on 20 May 2015). 
Aim
The aim of the present work was to evaluate the 
feasibility and safety of a novel myocardial regeneration 
strategy using WJMSCs as an off-the-shelf ‘unlimited’ 
therapeutic agent.
Material and methods
Patient enrollment, infarct size data and 
cardiac imaging
Consecutive patients with successful infarct-related 
artery (IRA) stent-assisted primary percutaneous coro-
nary intervention (pPCI) reperfusion (TIMI ≥ 2) in large 
AMI, defined as sustained left ventricular ejection frac-
tion (LVEF) reduction to ≤ 45% and peak creatine ki-
nase-MB (CK-MB) level exceeding 100  U/l (upper limit 
of normal (ULN) < 24 U/l), were screened for enrollment 
as described in our earlier protocols [14, 15] except that 
the present study group was not limited to left anteri-
or descending coronary artery (LAD) infarcts. Also, in the 
present study patients with two-vessel disease could be 
enrolled, but full coronary revascularization was required 
prior to cell transfer. No patients with three-vessel dis-
ease were recruited. The study was compliant with the 
Declaration of Helsinki and it was approved by the local 
Ethics Committee. All subjects provided informed written 
consent. 
Echocardiography, gadolinium-enhanced cardiac mag-
netic resonance imaging (cMRI) and ECG-gated single 
photon emission computed tomography (SPECT) were 
performed within 24–48  h prior to cell transfer as de-
scribed in our prior work [15]. 
Human WJMSCs harvest and expansion
The cells were harvested and prepared as described 
previously [2, 5, 7, 10]. Umbilical donations were ob-
tained following informed written consent, consistent 
with Directive 2004/23/EC, which sets the standards of 
quality and safety for the donation, procurement, test-
ing, processing, preservation, storage, and distribution of 
human tissues and cells. Cell preparation was consistent 
with the International Conference on Harmonization and 
the US Food and Drug Administration (FDA) guidelines 
on stem cell-based therapies [19]. All solutions were pre-
pared under Good Manufacturing Practice and all pro-
cedures were performed in line with Good Laboratory 
Practice. 
In brief, MSCs were isolated using an enzymatic di-
gestion strategy. Isolated cells were plated into 75 cm2 
tissue culture flasks (Sarstedt Stare Babice, Poland) in 
Dulbecco’s modified Eagle’s medium (PAA Laboratories 
GmbH, Goetzis, Austria) supplemented with 10% FBS 
(PAA Laboratories GmbH, Goetzis, Austria), PDGF (Pepro-
Tech Inc, Rocky Hill, USA) and EGF (PeproTech Inc, Rocky 
Hill, USA) growth factors. Flasks were incubated at 37°C 
in a humidified atmosphere containing 5% CO2, and af-
ter 7 days the medium was changed. At confluence, the 
adherent cells were detached using 0.25% trypsin and 
re-seeded at 0.075 × 106 cells/75 cm2 flask and incubat-
ed again until confluence with a weekly medium change. 
After the second passage, cells were collected and frozen 
in 2.5 × 106 aliquots in liquid nitrogen. Five–seven days 
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before treatment cells were thawed and expanded to ob-
tain at least 30 × 106 cells.
Wharton’s jelly mesenchymal stem cells 
preparation for human application
Phenotypic evaluation of cultured WJMSCs 
The MSC phenotype was analyzed with antibodies 
specific for MSCs (CD73, CD90, and CD105) and hema-
topoietic cells (CD45) (all antibodies from BD Bioscienc-
es, San Jose, USA) using a  FACSCalibur cytometer with 
CellQuest software (BD Biosciences Immunocytometry 
Systems, San Jose, USA). Wharton’s jelly mesenchymal 
stem cells used for transplantation were ≥ 95% positive 
for CD73, CD90, CD105 and negative for CD45, and their 
proliferative and functional capacity was evaluated.
Evaluation of cytogenetic stability of cultured 
WJMSCs
Cytogenetic stability of cultured WJMSCs was con-
firmed via GTG banding. Metaphases were analyzed 
under an Olympus BX51 microscope with a  camera 
(Olympus Corporation, Tokyo, Japan) to document pho-
tomicrographs. The CytoVision program (Leica Microsys-
tems Inc., Buffalo Grove, USA) was used to arrange chro-
mosomes into a karyogram.
Sterility evaluation and obtaining single-cell 
suspension
Sterility of the material was confirmed via micro-
biological evaluation. Immediately prior to transfer 
to the cathlab, WJMSCs were filtered to eliminate any 
potential cellular conglomerates that might cause mi-
crovascular plugging [20] and were suspended in 2 ml 
of 0.9% NaCl (B. Braun, Melsungen, Germany). In ad-
dition, the cells were gently tottered throughout the 
transport period to minimize any formation of cellular 
aggregates. 
Trans-IRA cell administration
Cell administration to the infarct zone was performed 
using the previously described non-coronary occlusive 
technique for transcoronary delivery of cellular thera-
pies [14, 21, 22]. 30 × 106 WJMSCs were re-suspended 
in 30 ml of 0.9% saline and were administered via the 
IRA using a cell-delivery perfusion catheter [14, 15], using 
a filter to eliminate any potential cellular conglomerates. 
The cell suspension infusion was at 2 ml/min, yielding 
2 × 106 cells per minute.
Clinical, angiographic and cardionecrotic 
marker evaluation 
Throughout the cell transfer, ECG was monitored care-
fully for any new ischemic changes or arrhythmias [14, 
21]. Angiographic recordings were performed to evaluate 
the coronary epicardial flow and myocardial tissue perfu-
sion using the established indices (TIMI grade, corrected 
TIMI frame count, cTFC) [23]. Hs-troponin T level (ULN 
< 0.014 ng/ml) was determined ≤ 24 h before and ≤ 24 h 
after cell transfer.
In-hospital follow-up and post-discharge 
patient monitoring
Twenty-four hours ECG recordings were performed 
24–48 h after cell administration. Close clinical vigilance 
has been applied for any adverse events up to 12 months 
(with further pre-specified points of analysis at every 
12 months up to 5 years). A  study-independent Safety 
Committee at the Jagiellonian University Department of 
Cardiac and Vascular Diseases performed initial event 
analysis in the context of the likelihood of the event as-
sociation with cell transfer, and it oversaw any potential 
EC notification(s).
This work is consistent with the US Food and Drug 
Administration (FDA) guidelines on stem cell-based ther-
apies [19]. 
Statistical analysis
Data are shown as mean ± SEM (min.-max.) or num-
ber (%). Two-tailed Student t-test was used for statistical 
comparisons (Statistica 10.0, StatSoft).
Results
Clinical characteristics of study patients and infarct 
size data are shown in Table I, indicating recruitment of 
a typical group of consecutive patients with a large, first 
acute myocardial infarction. 
Except for the WJMSC transfer using a  transradial 
approach at ≈ 5–7 days after pPCI, patient management 
was standard and was consistent with the European So-
ciety of Cardiology (ESC) guidelines. Myocardial imaging 
with SPECT and cMRI [15] was uncomplicated. No clinical 
complications occurred in the study group by the point 
of cell transfer. 
No WJMSC genetic instability was detected and no or 
other laboratory-level safety issues occurred. Wharton’s 
jelly mesenchymal stem cells transfer was performed 
per protocol in all study patients. No clinical symptoms 
or signs of myocardial ischaemia, and no new ischemic 
ECG changes occurred during or after WJMSC trans-IRA 
administration. 
There was no indication of any negative effect of 
trans-IRA WJMSC transfer on epicardial or myocardial 
perfusion. In particular, the epicardial flow was TIMI-3 
in all subjects before and after cell transfer, and cTFC 
was 45 ±8 (from 17 to 76) prior to cell transfer and 44 
±9 (from 15 to 77) after cell transfer (p = 0.51). Also, no 
patient showed a hs-troponin T rise after cell transcoro-
nary WJMSC transfer. The mean hs-troponin T level was 
0.92 ±0.29 (from 0.04 to 2.64) within 24 h before vs. 0.89 
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±0.28 (from 0.03 to 2.52 ng/ml) within 24 h after cell ad-
ministration (p = 0.04 for hs-troponin T decrease). 
One subject experienced, two days after cell trans-
fer, a transient temperature rise to 38.9°C; this was re-
active to paracetamol, with no signs of infection and no 
clinical sequel. The association between this event and 
cell transfer was considered possible, although transient 
fever may occur in the AMI recovery phase without any 
apparent cause other than myocardial necrosis [24].
One other patient had vein inflammation at the site 
of venous line insertion that was managed in a  typical 
manner, and another, treated empirically with amoxicillin 
due to chronic obstructive pulmonary disease infectious 
exacerbation, exhibited a  typical picture of amoxicil-
lin-associated skin rash that was responsive to steroid 
and antihistaminic administration and amoxicillin with-
drawal. Any potential association between the two latter 
events and WJMSC administration was judged, at the 
level of the Safety Committee, to be highly unlikely. 
All three events were reported to the local EC, and no re-
ciprocal safety concern was raised. No other adverse events 
and no significant arrhythmias (ECG Holter) occurred. 
At discharge, the patients were transferred to a rou-
tine post-AMI rehabilitation program. Up to 12 months 
there was one new, non-index territory AMI that led to 
death but no adverse events that might be attributable 
to WJMSC treatment.
In summary, the one and only adverse event that was 
considered potentially related to WJMSC administration 
was a transient temperature rise in 1 patient that was re-
sponsive to typical paracetamol treatment and resolved 
rapidly and without sequel. 
Discussion
The principal finding from this work is the feasibility 
and procedural safety of WJMSC use as an off-the-shelf, 
transcoronary cellular allogenic therapy in AMI in man. 
Our study also suggests further, post-procedural clinical 
safety of WJMSC cardiac transfer in humans, opening 
a new avenue towards controlled outcome studies using 
WJMSCs in AMI and in other conditions associated with 
depletion of functional myocardial tissue.
Regeneration therapies in the era of optimal 
pharmaco-mechanical AMI treatment: reversal 
of the damage as a logical step to follow 
maximized reduction of myocardial tissue loss 
Several lines of evidence suggest that, in AMI, con-
ventional pharmacological and mechanical therapies 
may have already reached the ceiling of efficacy (or are 
very close to such) in their capacity to limit myocardi-
al injury and reduce the infarct size [25]. The concept 
of myocardial injury reversal (as the next step to follow 
maximized limitation as explored and implemented over 
the last three decades) by stimulating myocardial regen-
eration is gradually gaining evidence of feasibility in the 
experimental and clinical setting, and cellular therapies 
are a pillar of this concept [3]. Nevertheless – and dis-
appointingly to those who have worked extensively to 
advance the field over the last years – the efficacy of cel-
lular therapies today remains too modest for any system-
atic clinical application [1, 3, 26]. Apart from the room for 
further improvement of cell delivery strategies [14, 16], 
important limiting factors are (i) lack of identification of 
sufficiently potent and clinically safe cell types, and (ii) in-
sufficient quantities of (in the majority of studies – autol-
ogous) regenerative cells and lack of their ‘off-the-shelf’ 
availability. Indeed, both experimental and clinical data 
indicate that the therapeutic effect of progenitor cells is 
dose (i.e. therapeutic cell number)-dependent [26–28]. 
Autologous non-expanded/engineered cell yields are 
usually rather small [14, 15], and cell harvesting in AMI 
is associated with important challenges of patient safety 
and logistics. On the other hand, it is likely that in AMI 
the optimal window for transcoronary-applied cellular 
therapies may be limited to the first ≈ 1–2 weeks [14], 
restricting the logistics of any autologous cell expansion 
strategies [16]. For these reasons, an intensive search is 
currently ongoing for clinically safe strategies using high 
regenerative potential allogenic cells available readily, on 
Table I. Study group (n = 10) characteristics and 
myocardial infarction parameters 
Variable Mean ± SEM (min.-max.) or n (%)
Age [years] 55.6 ±3 (32–65)
Women 5 (50)
Diabetes 3 (30)
Prior MI 0 (0)
IRA = LAD/Cx/RCA 6/3/1 (60/30/10)
IIb/IIIa rec. inhibitor (Abciximab) 4 (40)
IRA DES/BVS 9/1 (90/10)
IRA TIMI-3/TIMI-2* 8/2 (80/20)
Peak hs-troponin T [ng/ml] 17.3 ±9.1 (5.2–102.1)
Peak CK-MB [U/l] 533 ±89 (148–965)
Echo LVEF§ [%] 37.6 ±2.6 (21–43)
MRI LVEF§ [%] 40.3 ±2.7 (26–49)
G-SPECT LVEF§ [%] 36.8 ±2.8 (19–48)
MRI infarct size# [%] 20.1 ±2.8 (7–41)
SPECT infarct size# [%] 33.7 ±3.1 (18–52)
SEM – standard error of the mean, IRA – infarct-related artery, LAD/Cx/RCA – 
left anterior descending/circumflex/right coronary artery, LVEF – left ventricular 
ejection fraction, echo – echocardiography, SPECT – single photon emission 
computed tomography, G-SPECT = gated SPECT. *At pPCI completion (NB. at 
the cell transfer point all IRAs showed TIMI-3 flow), § ≤ 24 h from cell transfer to 
minimize the effect of myocardial stunning on LVEF as an acute index of infarct 
size [15], #expressed as proportion of left ventricular muscle volume (MRI) or as 
infarct extent (SPECT).
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an ad-hoc basis, and in sufficient numbers to address 
the clinical need to meaningfully reverse the myocardial 
injury burden that remains after successful AMI reperfu-
sion in order to reduce the scar formation and adverse 
myocardial remodeling, preventing arrhythmic death and 
heart failure.
Wharton’s jelly mesenchymal stem cells 
properties in relation to other regenerative cell 
types in cardiovascular medicine
Clinical translational research in the setting of AMI 
and heart failure to date has primarily employed autolo-
gous and non-expanded bone marrow cells [1, 26]. More 
recent approaches include lineage-engineered cells (ap-
plicable in a  chronic but not in the acute setting) [16]) 
and mesenchymal cells [18]. The use of bone marrow 
hematopoietic stem cells or mesenchymal stem cells 
from the bone marrow, adult organs and fetuses for myo-
cardial regeneration faces the disadvantages of invasive 
isolation, limited cell numbers and ethical constraints 
[6]. Allogenic cells, on the other hand, require no patient 
harvest and can be available in numbers larger than in 
the case of autologous cells. But allogenic cells elicit, in 
principle, an antigen-specific immune response of rejec-
tion by the recipient [29]. This is manifested by the host 
generation of specific anti-donor antibodies directed 
against the allogenic mesenchymal stem cells that may 
lead to immune-mediated elimination of the allogenic 
cells [29, 30]. Nevertheless, allogenic mesenchymal cells 
have been used in the context of myocardial regenera-
tion in animal models of AMI [18, 31] (where they were 
shown to home to the infarct border zone [31], similar to 
the bone marrow-derived hematopoietic CD34+ cells in 
humans [15, 32]), and there is at least one recent report 
of human cardiac use of allogenic bone marrow-derived 
mesenchymal stem cells [33]. The immune responses 
elicited by conventional allogenic mesenchymal cells are 
complex [29], and no long-term or large-scale safety data 
are available yet. 
Apart from ethics, immuno-rejection is the principal 
biologic limiting factor with (naturally allogenic) embry-
onic stem cells [6], whereas induced pluripotent stem 
cells face the key hurdle of potential tumorigenesis [6]. 
In that context, WJMSCs are unique as they are non-con-
troversial, can be harvested painlessly in abundance, are 
self-renewing and highly proliferative, possess stemness 
properties that last several passages in vitro, are multi-
potent but do not induce tumorigenesis even though 
they have a  number of embryonic cell markers [6, 11]. 
Expansion of WJMSCs is not associated with any loss of 
genetic stability [7], as these cells are not susceptible to 
spontaneous malignant transformation [34]. Importantly, 
WJMSCs do not express major histocompatibility com-
plex class II (HLA-DR) antigens or co-stimulatory immune 
response-associated surface antigens CD40, CD80, and 
CD86 [35]. When placed in an allogenic environment, 
WJMSCs are unable to elicit the response of immune-me-
diated rejection or proliferation of host immune cells [5, 
30, 35]. Thus in contrast to other allogenic mesenchymal 
cell types [30], WJMSCs do not elicit an allogenic immune 
response of transplant rejection [5, 30, 35].
In short, WJMSCs are uniquely immune-privileged; 
they are not rejected by an allogenic host and thus their 
allogenic transplantation is associated with no need for 
immunosuppression [5, 30, 35]. In addition, WJMSCs can 
be safely expanded to “as needed” quantities [5, 7, 10], 
can be phenotypically selected on a  large scale to cre-
ate repositories of distinct WJMSC populations [36], and 
– if needed – can be further reprogrammed/engineered 
towards the desired cell lines [10, 13, 37]. Moreover, ev-
idence is accumulating for WJMSCs’ successful use in 
engineering biological cardiac tissues [38–40] and an al-
logenic non-rejectable bioartificial heart [41].
Evidence for functional regenerative effect  
of WJMSCs in pre-clinical studies in AMI
The unique combination of high angiogenic and car-
diogenic potential of WJMSCs at bench [7, 11] with their 
low immunogenicity [35] makes these cells an important 
candidate for systematic in-vivo evaluation of myocardi-
al regenerative capacity [4]. Indeed, recent evidence in 
a porcine model of AMI demonstrated functionally sig-
nificant myocardial regeneration capacity of WJMSCs [9]. 
In particular, Zhang et al. [9] found that 40 × 106 WJM-
SCs transplanted by direct injections into the acutely 
infarcted area in the pig not only stimulated new ves-
sel formation but also survived and differentiated into 
cardiomyocytes and endothelial cells and promoted re-
cruitment and differentiation of native cardiac stem cells. 
In addition, WJMSC transplantation reduced apoptosis 
and fibrosis in the infarcted myocardium. A non-treated 
control group and a control group treated with placebo 
(phosphate-buffered saline) injections (sham procedure) 
were used as comparators. Overall, the multi-factorial re-
generative effect of 40 × 106 WJMSCs on the infracted 
tissue in situ translated into enhancement of viable myo-
cardium significant both statistically and functionally [9].
Taken together, evidence in large-animal AMI models 
shows, consistent with tissue data ex vivo [2, 11, 12] and 
small-animal AMI data [8, 10, 13], a functionally signifi-
cant effect of reduction of post-infarct adverse remodel-
ing and improvement of left ventricular function.
Choice of WJMSC dose for the human AMI 
study with transcoronary cell delivery
Evidence in experimental models of AMI shows that 
the therapeutic effect of progenitor cells is, in principle, 
dose-dependent [27]. Clinical evidence is overall con-
sistent with the animal work, as it indicates a positive 
correlation between the cell dose and the effect on LVEF 
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measured by echocardiography [28] or magnetic reso-
nance imaging [26], suggesting that maximized cell dos-
es should be used in the clinical setting. Nevertheless, 
there is also evidence that transcoronary delivery of (too) 
large cell doses (such as in the order of ≈ 50–75 million) 
can become harmful to myocardium via impairment of 
coronary blood flow in the IRA territory and producing 
microinfarcts that occur most likely via distal emboliza-
tion and microvascular plugging [20, 28, 42, 43].
Not only the absolute cell dose but also the cell infu-
sion rate may be associated with impairment of IRA flow 
and myocardial injury demonstrated by an increase in tro-
ponin levels and new microinfarcts on histopathology. In 
the sheep, an adverse effect of mesenchymal precursor 
cell trans-IRA infusion on epicardial flow associated with 
an increase in troponin levels and microinfarcts on histo-
pathology occurred with doses exceeding 40 million cells 
and infusion rates ≥ 2.5 million cells per minute, while 
lower cell doses and infusion rates had no effect on epi-
cardial perfusion or troponin release/microinfarct forma-
tion [20]. While a maximal total cell dose of 37.5 million 
was found to cause no acute myocardial injury in the 
sheep model of acute myocardial infarction in one study 
[20], a pilot study by another group showed, in a similar 
model, no late gadolinium enhancement on cardiac mag-
netic resonance imaging and only a small rise in tropo-
nin with the mesenchymal cell dose of 25 million (which 
might be due to the use of a  coronary-occlusive rather 
than non-occlusive cell delivery system) but a substantial 
troponin rise and a substantial de novo late gadolinium 
enhancement occurred only with the dose of 75 million 
cells [42]. For these reasons, in the present human study, 
an additional 20% safety margin was applied against 
the apparent myocardial safety of the 37.5 million mes-
enchymal cell dose in the study by Houtgraaf et al. [20]. 
This resulted in our selection of the dose of 30 million 
WJMSCs and infusion rate of 2 million cells per minute for 
the human study protocol. Our results demonstrated that 
trans-IRA infusion of 30 million WJMSCs at the rate of 
2 million cells per minute caused no deterioration of IRA 
epicardial flow (routine TIMI flow grade assessment) or 
tissue flow (cTFC evaluation). Moreover, no study subject 
showed a troponin increase ≤ 24 h after transcoronary cell 
transplantation.
Thus our findings are consistent with lack of any del-
eterious myocardial effect of WJMSC administration ac-
cording to the present study protocol.
Safety aspects of WJMSC therapy
There are at least three aspects of the safety of WJM-
SC therapy: (1) biological safety of cell harvest, banking, 
ex-vivo expansion and preparation for human use; (2) 
procedural safety of WJMSC transcoronary transfer that 
needs to include minimized risk of myocardial necrosis 
through microvessel plugging; and (3) short-and long-
term clinical safety of the allogenic biologic material use 
in humans. 
The present study identified transient temperature 
rise in a temporal relation to WJMSC transcoronary trans-
fer in one subject as the only adverse effect potentially 
associated with WJMSCs.
An association between WJMSC transfer and transient 
fever would be unsurprising, as this has been established 
in the mesenchymal stem cell clinical use literature [44]. 
Although no specific data in relation to WJMSCs seem to 
be available, this potential side effect has been reported 
using both autologous and allogenic mesenchymal cells, 
like in various human studies, and the overall odds ratio 
for transient fever was found to be at least 5-fold greater 
with mesenchymal cells than with placebo [44]. 
The temperature rise in a WJMSC-treated patient in 
our study was only transient, and it was fully responsive 
to paracetamol, leading to resolution without any sequel. 
As fever can occur in recent acute myocardial infarction in 
the absence of any cause other than myocardial necrosis 
(and the likelihood of its occurrence increases with the 
infarct size) [24], further work in a  large patient cohort 
including WJMSC-exposed and non-exposed subjects 
is needed to establish the prevalence of transient body 
temperature rise in potential relation to transcoronary 
WJMSC transfer. Indeed, further clinical studies in larger 
patient samples will need to continue close monitoring 
for any potential clinically relevant side effects of cardio-
vascular regeneration therapies using WJMSCs.
Limitations
The modest number of study participants may be 
considered a  relative limitation of our study. Neverthe-
less, the present work meets the criteria of a  first-in-
man feasibility and safety study, while we believe that 
further patients should be evaluated already within the 
framework of a randomized controlled study with blind-
ed analysis of potential therapeutic effects. Also, in the 
present study we did not perform any safety-focused 
WJMSC dose-response analysis. Apart from the require-
ment of large patient numbers for any dose-safety anal-
ysis, such potential evaluation was considered ethically 
unacceptable in the human setting. Rather, our choice of 
the WJMSC dose was based on careful analysis of the 
preclinical data (see above), and our selection involved 
the peak safe dose in large mammals with an additional 
20% safety margin.
All in all, the lack of any negative effect of WJMSCs 
in the dose used in the present study on epicardial flow 
or myocardial tissue perfusion, and no troponin release 
in relation to cell transfer, are consistent with myocar-
dial safety of the trans-IRA administration of 30 million 
WJMSCs as per the present human study protocol.
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Conclusions and further directions
This study demonstrated the feasibility and procedur-
al safety of WJMSC use as off-the-shelf cellular therapy 
in human AMI, and it suggested WJMSC cardiac transfer 
clinical safety throughout the follow-up period.
The present findings justify further investigation of 
the therapeutic potential of WJMSCs in humans with 
large AMI within the framework of a  randomized, pla-
cebo-controlled clinical study appropriately powered for 
pre-specified therapeutic endpoints. Consistent with the 
concept that regenerative cell effective uptake in the in-
farct area is an obligatory pre-requisite for seeking any 
therapeutic effect [15], further work needs to establish, 
as a bridge to the clinical outcome study, the magnitude 
of myocardial retention of WJMSCs in the therapeutic 
target zone in relation to that of other cell types used 
thus far in major clinical investigations [15, 17, 45].
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